Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124097 | 0.86 | PNMT (0.62) | PNMTMEN1KMT2APRCP | |
| SCHEMBL3126959 | 0.86 | PNMT (0.53) | PNMT | |
| SCHEMBL3124084 | 0.84 | PNMT (0.56) | PNMTMEN1KMT2ACXCR4PRCP | |
| SCHEMBL3119353 | 0.84 | PNMT (0.60) | PNMTMEN1KMT2ACXCR4PRCP | |
| SCHEMBL14997331 | 0.84 | PNMT (0.56) | PNMTMEN1KMT2APRCP | |
| SCHEMBL3125553 | 0.83 | PNMT (0.55) | PNMTMEN1KMT2ACXCR4PRCP | |
| SCHEMBL3127102 | 0.83 | PNMT (0.47) | PNMTMEN1KMT2A | |
| SCHEMBL3129933 | 0.83 | PNMT (0.55) | PNMTMEN1KMT2APRCP | |
| SCHEMBL3126873 | 0.81 | PNMT (0.46) | PNMT | |
| SCHEMBL3131056 | 0.80 | PNMT (0.51) | PNMTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | CCR3, CCR5, CCR1 | PNMT 1739/4885MEN1 2946/4885KMT2A 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.